Addus HomeCare (ADUS) PT Raised to $119 at TD Cowen

TD Cowen analyst Ryan Langston raised the price target on Addus HomeCare (NASDAQ: ADUS) to $119.00 (from $105.00) while maintaining a Buy rating.

The analyst commented, "ADUS posted a 1Q24 EBITDA result 7% better than consensus. We are raising our annual estimates in 2024 by 5% and 2025 by 4% mainly on better than expected G&A leverage and higher PCS rates. We raise our price target to 119 and reiterate our Buy rating. "

You May Also Be Interested In

• ADC Therapeutics (ADCT) PT Lowered to $5 at Guggenheim
• Acadia Pharmaceuticals (ACAD) PT Raised to $49 at UBS
• The Elmet Group (ELMT) PT Raised to $21 at Canaccord